Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fabrazyme Market Could Grow With Dialysis Patients, Women, Children

Executive Summary

Genzyme expects the Fabry disease incidence in dialysis patients to nearly double the market for its Fabry therapy Fabrazyme

You may also be interested in...



Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed

FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval

TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model

Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions

CMS Medicare Self-Injectable Guidelines Maintain Split Within Drug Classes

The Centers for Medicare & Medicaid Services' self-injectables guidelines would still divide Medicare coverage within a therapeutic drug class based on route of administration

Related Content

UsernamePublicRestriction

Register

PS041733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel